Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Industry Will Sell Medicare Bill; Card Launch Will Be First Test

Executive Summary

PhRMA's efforts to support the roll-out of the Medicare prescription drug benefit will begin with the use of industry sales reps to deliver educational material, incoming Pharmaceutical Research & Manufacturers of America Chairman Miles White (Abbott) told the association's annual meeting in Palm Beach, Fla. April 3

You may also be interested in...



Wyeth More Optimistic About Medicare Rx; Protonix May Benefit

Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30

Wyeth More Optimistic About Medicare Rx; Protonix May Benefit

Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30

HHS Rx Price Negotiations Could Gain Bipartisan Support, Consultant Says

Congress will move to strike down the Medicare Rx law's "non-interference" provision in the next two years, former Senate Finance Committee health advisor Kathleen Means said at the Biotechnology Industry Organization's annual conference in San Francisco June 9

Related Content

UsernamePublicRestriction

Register

PS043736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel